

Ad hoc announcement pursuant to Art. 53 LR

Basel, 22 July 2021

Roche reports good half-year results

- **Group sales** up 8%¹ at constant exchange rates (CER); 5% in Swiss francs
- **Pharmaceuticals Division sales** decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars
- **Diagnostics Division sales** grow 51% due to high demand for COVID-19 tests and strong momentum in routine testing
- **IFRS net income** increases by 2% (-3% in Swiss francs), while core earnings per share up 6%
- **Highlights** in the second quarter:
 - **Pipeline:** Positive study results for immunotherapy Tecentriq in early lung cancer; encouraging data strengthen Roche's portfolio in neurosciences and hard-to-treat blood cancers
 - **EU approvals:** Tecentriq (specific type of metastatic non-small cell lung cancer), Venclyxto-based combinations (acute myeloid leukaemia) and Enspryng (neuromyelitis optica spectrum disorder, a rare autoimmune disease of the CNS)
 - **GenMark Diagnostics:** Acquisition, completed in April, broadens Roche's molecular lab portfolio and reinforces our commitment to fight infectious diseases and antibiotic resistance
 - **COVID-19:** Additional positive study results for antibody combination Ronapreve (co-developed with Regeneron) and AT-527 (co-developed with Atea); Japan becomes first country to approve Ronapreve for the treatment of mild to moderate COVID-19; FDA Emergency Use Authorization for Actemra/RoActemra; launch of further tests reinforces Roche's position as a global leader in COVID-19 diagnostics
- **Outlook** for 2021 confirmed

Key figures January - June 2021	CHF millions		% change	
	2021	2020	At CER ¹	In CHF
Group sales	30,713	29,281	8	5
Pharmaceuticals Division	21,671	23,202	-3	-7
Diagnostics Division	9,042	6,079	51	49
Core operating profit	11,652	11,766	4	-1
Core EPS - diluted (CHF)	10.56	10.44	6	1
IFRS net income	8,216	8,465	2	-3

Commenting on the Group's performance in the first six months, Roche CEO Severin Schwan said: "We have achieved good results in the first half, primarily thanks to the demand for our new medicines and COVID-19 tests. The Pharma Division began to grow again in the second quarter. The base diagnostics business shows strong momentum. As expected, demand for COVID-19 tests peaked in the second quarter. I'm particularly excited about the significant progress we made in our product pipeline, including very promising study results for Tecentriq in early-stage lung cancer, as well as additional positive data for Evrysdi in spinal muscular atrophy and for COVID-19 medicines. Based on the good results of the first half of 2021, we confirm the outlook for the full year."

Outlook confirmed for 2021

Despite the continued strong impact of biosimilars, sales are expected to grow in the low- to mid-single digit range, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to increase its dividend in Swiss francs further.

Group results

In the first half of the year, **Group** sales rose 8% (5% in CHF) to CHF 31 billion. IFRS net income increased 2% (-3% in CHF), while core earnings per share up by 6%. The appreciation of the Swiss franc against most currencies had a negative impact on the results expressed in Swiss francs compared to constant exchange rates.

Sales in the **Pharmaceuticals Division** were CHF 22 billion, a decrease of 3%. However, while sales in the first quarter were still strongly affected by COVID-19 (-9%), the second quarter showed signs of recovery in some regions (+4%). The ongoing impact from biosimilars, particularly in the US, resulted in a sales decrease of CHF 2.8 billion.

The new medicines (launched since 2012²) continued their strong growth (+30%, or +CHF 2.6 billion). In the first six months, they generated sales of over CHF 11 billion, thus already contributing more than 50% to the division's total sales.

In the **United States**, sales decreased by 8%, due to the launches of biosimilars for the cancer medicines MabThera/Rituxan, Avastin and Herceptin (combined -49% or CHF 1.7 billion) and the pandemic. This decline was partially compensated for by the new medicines – mainly Ocrevus (multiple sclerosis), Hemlibra (haemophilia), Evrysdi (spinal muscular atrophy) and Tecentriq (cancer immunotherapy). Here too, business is showing signs of recovery: after -14% in the first quarter, sales in the second quarter were stable, i.e. at the previous year's level.

Sales in **Europe** grew by 4%, with new product sales more than compensating for the impact from biosimilars and the pandemic. Ronapreve, the antibody combination against COVID-19, was the key growth driver, mainly in Germany, Italy and France.

In **Japan**, sales were stable. Growth of recently launched medicines, such as Tecentriq and Enspryng, was offset by the impact from biosimilars and government price cuts.

Sales in the **International region** grew by 2%. Growth in China (+3%) was mainly due to strong sales of Perjeta, Alecensa, Tecentriq and Herceptin, partly offset by biosimilar competition for Avastin and MabThera/Rituxan. Excluding China, sales increased by 1%, mainly due to orders for Ronapreve in India, again partially offset by the impact from biosimilars, mainly in Canada and Brazil.

The **Diagnostics Division** achieved very strong sales growth of 51% to CHF 9 billion. The base business (i.e. routine diagnostics), which was heavily impacted by the pandemic in 2020, grew strongly: +17% in the first quarter and +31% in the second quarter. Roche's industry-leading portfolio of COVID-19 tests contributed total sales of CHF 2.5 billion (CHF 0.7 billion in 2020); the demand for COVID-19 tests is likely to decrease in the second half of 2021.

The division recorded high sales growth in all regions: **Europe, Middle East and Africa** +70%, **Asia-Pacific** +44%, **North America** +25% and **Latin America** +77%.

In April, Roche acquired the US company **GenMark Diagnostics** for USD 1.9 billion. GenMark's novel technology detects a wide range of pathogens from a single patient sample. It broadens Roche's molecular lab portfolio, and reinforces our commitment to help control infectious diseases and antibiotic resistance.

Roche's response to the COVID-19 pandemic

Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, more treatment options are still needed. In the second quarter, Roche and/or its partners shared positive news:

- Antibody combination Ronapreve (co-developed with Regeneron): Preliminary phase III data from a University of Oxford-led trial demonstrated that the antibody combination casirivimab/imdevimab reduced the risk of death when given to patients hospitalised with severe COVID-19 who had not mounted a natural antibody response of their own. In July, Japan became the first country to approve Ronapreve for the treatment of patients with mild to moderate COVID-19.
- AT-527 (co-developed with Atea): Interim results from a phase II trial indicated rapid and sustained antiviral activity against SARS-CoV-2 in hospitalised COVID-19 patients. AT-527 continues to be evaluated for the treatment and prevention of COVID-19.
- Actemra/RoActemra:³ Roche's intravenous anti-inflammation medicine received FDA Emergency Use Authorization (EUA) for the treatment of severe COVID-19 in hospitalised adults and children.
- Manufacturing: Roche is currently ramping up its production capacity for AT-527, which requires a complex manufacturing process, as much as possible. For Actemra, Roche has already increased its own production capacity significantly and has been working with external manufacturers on transferring its technologies to increase the global supply further.

Roche has also reinforced its position as a world-leading supplier of COVID-19 diagnostics. In June, the **SARS-CoV-2 Antigen Self Test Nasal** obtained the CE mark,⁴ and the **cobas SARS-CoV-2 Nucleic acid test** for use on the cobas Liat System was granted first FDA EUA for PCR testing of both symptomatic and asymptomatic individuals at the point of care (with results within 20 minutes).

Pharmaceuticals: major approvals; positive data in neuroscience and oncology

In addition to all the efforts in the fight against the pandemic, Roche has continued to develop innovative medicines for other serious diseases. In the second quarter, Roche reported a number of regulatory achievements:

In May, the European Commission approved **Venclyxto**⁵-based combinations for adults with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, and Tecentriq as a first-line monotherapy treatment for people with a specific type of metastatic non-small cell lung cancer.

In June, the FDA granted priority review for Roche's **Port Delivery System (PDS)** with **ranibizumab** for the treatment of neovascular or "wet" age-related macular degeneration. If approved, it would be the first and only eye implant with continuous drug delivery – an alternative to frequent eye injections.

Also in June, the European Commission approved **Enspryng** as the first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) for both adults and adolescents. NMOSD is a rare autoimmune disease of the central nervous system that can cause permanent blindness, muscle weakness and paralysis.

Furthermore, Roche presented positive data in neurosciences and oncology:

Roche's data across its growing neuroscience portfolio, presented at several medical congresses, demonstrates our continued commitment to developing breakthrough medicines for challenging neurological conditions. New data for **Enspryng** (NMOSD) and **Evrysdi** (spinal muscular atrophy, SMA) reinforced the efficacy and safety profile of both medicines, including early, very encouraging trial results for Evrysdi in pre-symptomatic infants under two months of age. Data for **Ocrevus** (relapsing and primary progressive multiple sclerosis, MS) showed consistent benefit on slowing disease progression in both forms of MS.

In addition, Roche presented new data from 19 approved and investigational medicines across 20 cancer types at the American Society of Clinical Oncology congress. One of the highlights was the highly promising immunotherapy data in early lung cancer. It showed that **Tecentriq** improved disease-free survival in people with resectable early-stage non-small cell lung cancer compared to best supportive care – a first in cancer immunotherapy.

The latest advances with immunotherapies in non-Hodgkin lymphoma were also encouraging: data from the emerging T-cell engaging bispecific antibodies, **mosunetuzumab** and **glofitamab**, and the antibody-drug conjugate, Polivy, show the potential of these novel immunotherapeutic approaches for people with various types of blood cancer.

The outlook of Roche's haematology franchise was strengthened further with new data from three pivotal phase III studies. These data, presented at the annual haematology congress EHA, reinforced the efficacy of **Venclexta/Venclyxto** combinations in hard-to-treat blood cancers.

Pharmaceuticals: major clinical and regulatory news flow up to mid-July 2021

	Compound	Indication	Milestone
Regulatory	Xofluza	Influenza: Healthy people; high-risk people; post exposure	EU approval
	Evrysdi	Spinal muscular atrophy (SMA) type 1/2/3	EU approval
	faricimab	Diabetic macular oedema/neovascular age-related macular degeneration (nAMD)	US/EU joint filing
	Tecentriq	First-line PDL1+ non-small cell lung cancer (NSCLC)	EU approval
	Venclexta + azacitidine	Acute myeloid leukaemia	EU approval
Phase III / pivotal readouts	faricimab	nAMD	Ph III TENAYA/LUCERNE
	casirivimab/imdevimab	SARS-CoV-2 outpatient	Ph III study 2067
	casirivimab/imdevimab	SARS-CoV-2 post-exposure prophylaxis	Ph III study 2069
	Tecentriq	Adjuvant NSCLC	Ph III IMpower010
	Evrysdi	SMA type 1/2/3 switching study	Ph II JEWELFISH

Diagnostics: important launches in cardiovascular and oncology

Providing accurate and timely testing has never been more vital. Roche continues to invest heavily in diagnostic innovation to help meet the changing demands of healthcare systems beyond COVID-19.

In April, Roche launched new ways (claim extensions) to use their **cardiovascular tests**, empowering clinicians to improve screening, diagnosis and treatment of millions of people. These gold standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (Troponin T) and manage heart failure more effectively (NT-proBNP).

Also in April, Roche received US approval for the first companion diagnostic, **VENTANA MMR RxDx Panel**, to identify cancer patients best suited for treatment with a specific GSK immunotherapy.

Pharmaceuticals sales

Sales January - June 2021	CHF millions		As % of sales		% change	
	2021	2020	2021	2020	At CER	In CHF
Pharmaceuticals Division	21,671	23,202	100.0	100.0	-3	-7
United States	10,802	12,464	49.8	53.7	-8	-13
Europe	4,485	4,190	20.7	18.1	4	7
Japan	1,808	1,908	8.3	8.2	0	-5
International*	4,576	4,640	21.2	20.0	2	-1

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

Top-selling pharmaceuticals	Total		United States		Europe		Japan		International*	
	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
Ocrevus	2,438	23	1'849	18	422	38	-	-	167	60
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Avastin	1,645	-40	530	-47	257	-69	330	-4	528	-12
Actemra/RoActemra	1,642	17	689	6	456	16	182	6	315	63
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Herceptin	1,396	-35	348	-56	277	-25	43	-40	728	-19
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
MabThera/Rituxan	1,379	-41	855	-46	134	-35	20	-35	370	-27
Kadcyla	959	19	401	6	336	27	60	56	162	31
Xolair	887	-1	887	-1	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

Pharmaceuticals: established products

Avastin (CHF 1.6 billion -40%). Advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, relapsed glioblastoma (a type of brain tumour) and liver cancer in combination with Tecentriq. Sales were strongly impacted by the launch of biosimilars, mainly in the US and Europe.

Actemra/RoActemra (CHF 1.6 billion, +17%). Rheumatoid arthritis, forms of juvenile idiopathic arthritis and giant cell arteritis as well as CAR T cell-induced severe or life-threatening cytokine release syndrome. Growth was driven by the fact that a number of countries included this medicine in their treatment guidelines for severe COVID-19-associated pneumonia. The International region and Europe were the major contributors to this sales increase.

Herceptin (CHF 1.4 billion, -35%). HER2-positive breast cancer and HER2-positive metastatic gastric cancer. Sales decrease was mainly due to biosimilar launches in the US and Europe.

MabThera/Rituxan (CHF 1.4 billion, -41%). Forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Sales were lower due to the biosimilar erosion as well as COVID-19 pandemic restrictions.

Xolair (CHF 887 million, -1%, US only). Chronic idiopathic urticaria and allergic asthma. Sales growth in the chronic idiopathic urticaria indication was offset by competition in the allergic asthma indication. Xolair remains the market leader in the larger allergic asthma indication.

Lucentis (CHF 665 million, -3%, US only). Eye conditions, including 'wet' age-related macular degeneration. Sales decreased, based on the continued impact of the COVID-19 pandemic (patients delaying treatment).

Pharmaceuticals: medicines launched since 2012

Ocrevus (first approved in 2017; CHF 2.4 billion, +23%). Relapsing and primary progressive forms of multiple sclerosis; 2-hour only infusion. The demand for this treatment in both indications remained strong, while the pandemic still had a certain negative impact. In the US, growth was driven both by new and returning patients, with a higher proportion of sales coming from returning patients.

Perjeta (first approved in 2012; CHF 2 billion, +5%). HER2-positive breast cancer. Sales increased mostly due to the high demand in China in both early and metastatic breast cancer settings.

Tecentriq (first approved in 2016; CHF 1.6 billion, +29%). Cancer immunotherapy for various types of cancer (either alone or in combinations), e.g. certain types of lung, bladder, breast and liver cancer. Sales growth in all regions, notably Japan, primarily due to the growth in the treatment of hepatocellular carcinoma (HCC). In the US, sales were higher driven by the new indications for first-line non-small cell lung cancer (NSCLC) and HCC.

Hemlibra (first approved in 2017; CHF 1.4 billion, +45%). Haemophilia A with and without factor VIII inhibitors; only prophylactic treatment that can be administered subcutaneously once weekly, every two or every four weeks. Sales continued to show a strong uptake, especially in the US and Europe.

Kadcyla (first approved in 2013; CHF 959 million, +19%). HER2-positive breast cancer. Sales growth was driven by Kadcyla's usage in the early breast cancer setting. Sales benefited from patients switching to the new standard of treatment.

Alecensa (first approved in 2015; CHF 631 million, +20%). ALK-positive non-small cell lung cancer. The global uptake continued with sales growth across all regions; the International Region and Europe were the main drivers.

Ronapreve (first approved in 2021; FDA EUA in 2020 for Regeneron; CHF 595 million*). Antibody combination casirivimab/imdevimab for the treatment of recently diagnosed high-risk patients with mild to moderate COVID-19. Roche and Regeneron are collaborating on developing and manufacturing the medicine; Roche is responsible for distribution in Europe and other countries outside the US. There was a strong uptake, mainly in Germany, India, Italy and France.

Esbriet (first approved in 2014; CHF 526 million, -3%). Idiopathic pulmonary fibrosis (IPF).

Gazyva/Gazyvaro (first approved in 2013; CHF 324 million, +8%). Chronic lymphocytic leukaemia, rituximab-refractory follicular lymphoma and previously untreated advanced follicular lymphoma.

Evrysdi (first approved in 2020; CHF 243 million*). Spinal muscular atrophy (SMA) in adults and children two months of age and older. Evrysdi helps infants to survive without permanent ventilation; the first and only medicine for SMA that can be taken at home. The new SMA medicine continued to show a strong uptake, mainly in the US and Russia.

Erivedge (first approved in 2012; CHF 127 million, -9%). Advanced basal cell carcinoma.

Phesgo (first approved in 2020; CHF 96 million*). Early and metastatic HER2-positive breast cancer (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection). Offers faster administration in just minutes, compared to hours with standard intravenous administration.

Polivy (first approved in 2019; CHF 94 million, +17%). Relapsed or refractory diffuse large B-cell lymphoma; part of combination therapy; a fixed-duration treatment option for people with this aggressive form of lymphoma.

Enspryng (first approved in 2020; CHF 39 million*). Rare autoimmune disease of the central nervous system (neuromyelitis optica spectrum disorder; NMOSD); first subcutaneous NMOSD treatment that can be self-administered at home. The medicine continues to show a good uptake, despite COVID-19 restrictions having some impact on potential new patients.

Rozlytrek (first approved in 2019; CHF 22 million, +182%). Specific form of non-small cell lung cancer (NSCLC); solid tumours expressing a specific gene fusion; ROS1-positive, advanced NSCLC.

* recently launched, no growth figures available

Diagnostics sales

Sales January - June 2021	CHF millions		As % of sales		% change	
	2021	2020	2021	2020	At CER	In CHF
Diagnostics Division	9,042	6,079	100.0	100.0	51	49
Customer Areas						
Core Lab	3,726	2,821	41.2	46.4	34	32
Molecular Lab	2,216	1,558	24.5	25.6	45	42
Point of Care	1,616	360	17.9	5.9	349	349
Diabetes Care	894	832	9.9	13.7	10	7
Pathology Lab	590	508	6.5	8.4	20	16
Regions						
Europe, Middle East, Africa	4,144	2,408	45.8	39.5	70	72
North America	2,055	1,740	22.7	28.8	25	18
Asia-Pacific	2,293	1,588	25.4	26.1	44	44
Latin America	550	343	6.1	5.6	77	60

Core Lab. Focuses on central labs; provides diagnostics solutions in the areas of immunoassays, clinical chemistry and custom biotech. Sales increased by 34%, due to the ongoing recovery of routine testing in all regions (with the largest contribution coming from Asia-Pacific) and COVID-19-related testing. Its immunodiagnostics business grew 40%.

Molecular Lab. Focuses on molecular labs; provides diagnostics solutions for the detection and monitoring of pathogens, donor screening, sexual health and genomics. Sales grew by 45% led by COVID-19 testing, such as the high-throughput PCR tests. Its virology business grew 60%. Sales were higher in all regions, led by the EMEA region and North America.

Point of Care. Focuses on diagnostics solutions at the point of care, e.g. in emergency rooms, medical practices or directly with patients; includes SARS-CoV-2 rapid tests, blood gas and electrolyte tests. Significant sales growth of 349%; the SARS-CoV-2 Rapid Antigen test was the main growth driver, especially in the EMEA region.

Diabetes Care. Focuses on integrated personalised diabetes management for people with diabetes and healthcare professionals. Sales increased by 10%, driven by its blood glucose monitoring business (such as the Accu-Chek Guide system).

Pathology Lab. Focuses on pathology labs; provides diagnostics solutions for tissue biopsies and companion diagnostics. Sales increased by 20%. This was mainly due to growth in the advanced staining and in the companion diagnostics businesses.

Roche's Half Year Results 2021 – Live Webinar

There will be a live webinar for investors and analysts today, **Thursday, 22 July at 2:00 pm CEST**. To access the webinar, please click [here](#).

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Additional information

- Half Year 2021 Presentation: <https://www.roche.com/irp210722-a.pdf>
- Half Year 2021 Presentation with appendix: <https://www.roche.com/irp210722.pdf>
- Digital Half Year Report 2021: <https://www.roche.com/hy21e.pdf>
- Annual Report: <https://www.roche.com/investors/annualreport20.htm>

Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this Annual Report, such as: (1) pricing and product initiatives of

competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for 2020 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche

References

- [1] Unless otherwise stated, all growth rates and comparisons to prior year in this document are at constant exchange rates (CER: average 2020) and all total figures quoted are reported in CHF.
- [2] Launched since 2012: Erivedge, Perjeta, Kadcyła, Gazyva/Gazyvaro, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluzo, Polivy, Rozlytrek, Plesgo, Enspryng, Evrysdi and Ronapreve (casirivimab/imdevimab).
- [3] Actemra/RoActemra is currently not approved for this use.
- [4] An early version has already been available in a number of European countries since February 2021 (local special approval pathways).
- [5] Venclexta/Venclexto is being developed by AbbVie and Roche.

Roche Investor Relations

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: karl.mahler@roche.com

Jon Kaspar Bayard

Phone: +41 61 68-83894

e-mail: jon_kaspar.bayard@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com

Appendix: Tables

1.	Sales January to June 2021 and 2020	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2021 vs. HY 2020.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2021 vs. HY 2020	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2021 vs. HY 2020.....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	11
11.	Roche Group consolidated income statement for the six months ended 30 June 2021.....	12
12.	Roche Group core results reconciliation – Half Year 2021	13
13.	Divisional core results reconciliation – Half Year 2021.....	14
14.	Roche Group consolidated balance sheet	15
15.	Roche Group consolidated statement of cash flows	16

1. Sales January to June 2021 and 2020

CHF millions	Six months ended 30 June		% change	
	2021	2020	At CER	In CHF
Pharmaceuticals Division	21,671	23,202	-3	-7
United States	10,802	12,464	-8	-13
Europe	4,485	4,190	4	7
Japan	1,808	1,908	0	-5
International*	4,576	4,640	2	-1
Diagnostics Division	9,042	6,079	51	49
Roche Group	30,713	29,281	8	5

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Pharmaceuticals Division	10,940	-6	11,115	-4	10,215	-7	10,600	-9	11,071	4
United States	5,848	-10	5,925	-5	5,258	-13	5,292	-14	5,510	0
Europe	1,926	-3	2,078	2	1,930	-8	2,175	-6	2,310	15
Japan	960	-7	894	-13	963	-5	852	-7	956	7
International*	2,206	5	2,218	-2	2,064	11	2,281	0	2,295	4
Diagnostics Division	3,198	2	3,583	18	4,129	28	4,330	55	4,712	48
Roche Group	14,138	-4	14,698	1	14,344	1	14,930	3	15,783	14

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2021 vs. HY 2020

Top-selling pharmaceuticals January - June 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Avastin	1,645	-40	530	-47	257	-69	330	-4	528	-12
Actemra/RoActemra	1,642	17	689	6	456	16	182	6	315	63
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Herceptin	1,396	-35	348	-56	277	-25	43	-40	728	-19
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
MabThera/Rituxan	1,379	-41	855	-46	134	-35	20	-35	370	-27
Kadcyla	959	19	401	6	336	27	60	56	162	31
Xolair	887	-1	887	-1	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2021 vs. HY 2020

New products January - June 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	127	-9	81	-13	30	-5	-	-	16	12
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Kadcyla	959	19	401	6	336	27	60	56	162	31
Gazyva/Gazyvaro	324	8	153	13	106	2	31	-9	34	22
Esbriet	526	-3	361	-4	137	-1	-	-	28	-4
Cotellic	24	-6	7	25	9	-25	-	-	8	0
Alecensa	631	20	167	6	148	15	118	9	198	52
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
Xofluza	-8	-	-8	-	-	-	-	-	-	-
Polivy	94	17	40	-24	41	52	8	-	5	**
Rozlytrek	22	182	14	112	3	**	3	367	2	**
Phesgo	96	-	52	-	39	-	-	-	5	-
Enspryng	39	-	8	-	-	-	30	-	1	-
Evrysdi	243	-	166	-	27	-	-	-	50	-
Ronapreve	595	-	-	-	483	-	-	-	112	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2021 vs. HY 2020

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Avastin	1,645	-40	530	-47	257	-69	330	-4	528	-12
Actemra/RoActemra	1,642	17	689	6	456	16	182	6	315	63
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Herceptin	1,396	-35	348	-56	277	-25	43	-40	728	-19
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
MabThera/Rituxan	1,379	-41	855	-46	134	-35	20	-35	370	-27
Kadcyla	959	19	401	6	336	27	60	56	162	31
Xolair	887	-1	887	-1	-	-	-	-	-	-
Lucentis	665	-3	665	-3	-	-	-	-	-	-
Alecensa	631	20	167	6	148	15	118	9	198	52
Activase/TNKase	598	-8	570	-9	-	-	-	-	28	-2
Ronapreve	595	-	-	-	483	-	-	-	112	-
Esbriet	526	-3	361	-4	137	-1	-	-	28	-4
Gazyva	324	8	153	13	106	2	31	-9	34	22
CellCept	298	-4	23	-25	77	-6	35	-8	163	1
Pulmozyme	276	-18	173	-25	60	-14	0	-16	43	16
Evrysdi	243	-	166	-	27	-	-	-	50	-
Mircera	214	-12	-	-	27	-15	60	-16	127	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	964	12	1,198	37	1,052	10	1,226	16	1,212	31
Perjeta	930	12	988	17	954	20	988	2	980	7
Avastin	1,338	-24	1,188	-30	969	-35	863	-40	782	-40
Actemra/RoActemra	795	40	673	27	724	29	779	22	863	12
Tecentriq	653	54	718	49	723	35	775	26	824	31
Herceptin	993	-33	879	-38	653	-43	755	-35	641	-35
Hemlibra	482	59	572	57	615	45	661	33	732	58
MabThera/Rituxan	1,051	-32	1,003	-33	780	-43	705	-46	674	-34
Kadcyla	409	26	458	33	450	26	478	17	481	21
Xolair	490	1	493	3	453	3	409	-6	478	3
Lucentis	341	-25	392	-5	324	-22	337	-7	328	2
Alecensa	272	27	301	37	319	54	298	14	333	25
Activase/TNKase	301	-3	314	1	316	11	304	-17	294	3
Ronapreve	-	-	-	-	-	-	166	-	429	-
Esbriet	274	2	278	5	264	-9	256	-8	270	1
Gazyva	145	23	162	15	160	6	155	-2	169	18
CellCept	148	-2	148	-11	144	-1	154	-5	144	-3
Pulmozyme	161	-10	148	-16	142	-17	139	-23	137	-13
Evrysdi	-	-	8	-	47	-	80	-	163	-
Mircera	125	-7	118	-26	101	-24	105	-13	109	-10

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

[illegible]

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	141	26	193	56	184	20	217	37	205	40
Perjeta	260	1	291	13	292	4	301	-3	277	2
Avastin	373	-13	286	-33	170	-61	138	-68	119	-69
Actemra/RoActemra	173	2	186	10	215	24	239	12	217	20
Tecentriq	137	90	155	72	139	18	168	14	171	20
Herceptin	168	-33	161	-30	143	-31	146	-25	131	-25
Hemlibra	68	92	115	171	112	99	136	71	156	123
MabThera/Rituxan	79	-44	102	-29	75	-36	69	-45	65	-21
Kadcyla	125	26	147	39	156	34	167	24	169	29
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	59	27	68	22	71	22	74	11	74	19
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	166	-	317	-
Esbriet	60	-3	64	-2	68	2	69	-10	68	9
Gazyva	45	13	54	26	56	15	51	-11	55	19
CellCept	32	-20	39	-8	38	-10	38	-22	39	17
Pulmozyme	31	0	31	3	34	4	30	-20	30	-7
Evrysdi	-	-	-	-	-	-	-	-	27	-
Mircera	14	-13	14	-14	13	-17	13	-23	14	-7

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	75	11	70	-9	75	0	64	-11	68	-2
Avastin	182	-19	171	-25	183	-7	161	-8	169	0
Actemra/RoActemra	92	-8	86	-15	99	1	84	-2	98	15
Tecentriq	79	94	77	62	105	75	120	82	137	86
Herceptin	37	-45	32	-46	31	-43	22	-43	21	-37
Hemlibra	77	36	76	13	86	15	79	11	87	21
MabThera/Rituxan	16	-45	15	-38	16	-34	10	-37	10	-34
Kadcyla	23	3	22	7	27	41	27	54	33	57
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	62	8	58	8	67	29	55	8	63	10
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	21	65	15	-36	18	-9	14	1	17	-17
CellCept	21	-6	19	-3	21	1	17	-9	18	-7
Pulmozyme	0	12	1	40	0	-15	0	-23	0	-9
Evrysdi	-	-	-	-	-	-	-	-	-	-
Mircera	38	-29	39	-20	40	-18	29	-18	31	-15

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	50	43	66	74	70	55	95	77	72	41
Perjeta	220	50	259	52	249	135	263	23	292	34
Avastin	312	-6	299	-14	310	8	277	-4	251	-20
Actemra/RoActemra	134	123	151	209	140	114	151	134	164	27
Tecentriq	69	120	64	74	79	86	92	84	100	56
Herceptin	415	-14	373	-28	284	-29	396	-16	332	-22
Hemlibra	26	319	25	58	49	325	48	214	50	92
MabThera/Rituxan	236	-25	214	-30	190	-24	200	-23	170	-30
Kadcyla	61	12	76	30	77	50	84	28	78	35
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	67	107	86	141	95	**	92	44	106	59
Activase/TNKase	13	4	12	-5	14	1	13	-10	15	6
Ronapreve	-	-	-	-	-	-	-	-	112	-
Esbriet	14	3	14	5	10	-9	14	0	14	-7
Gazyva	14	16	15	5	15	-1	16	21	18	23
CellCept	81	18	75	-10	70	4	88	11	75	-8
Pulmozyme	14	-25	17	-6	14	-7	24	3	19	40
Evrysdi	-	-	-	-	1	-	1	-	49	-
Mircera	73	13	65	-31	48	-30	63	-8	64	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

11. Roche Group consolidated income statement for the six months ended 30 June 2021

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	21,671	9,042	-	30,713
Royalties and other operating income	1,372	48	-	1,420
Cost of sales	(4,515)	(4,477)	-	(8,992)
Marketing and distribution	(3,086)	(1,403)	-	(4,489)
Research and development	(6,280)	(830)	-	(7,110)
General and administration	(849)	(334)	(282)	(1,465)
Operating profit	8,313	2,046	(282)	10,077
Financing costs				(211)
Other financial income (expense)				21
Profit before taxes				9,887
Income taxes				(1,671)
Net income				8,216
Attributable to				
- Roche shareholders				7,803
- Non-controlling interests				413
Earnings per share and non-voting equity security				
Basic (CHF)				9.14
Diluted (CHF)				9.05

12. Roche Group core results reconciliation – Half Year 2021

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	30,713	-	-	-	-	-	-	-	-	30,713
Royalties and other operating income	1,420	-	-	-	-	-	-	-	-	1,420
Cost of sales	(8,992)	88	656	-	11	-	-	-	-	(8,237)
Marketing and distribution	(4,489)	180	17	-	-	-	-	-	-	(4,292)
Research and development	(7,110)	98	157	165	-	-	-	-	-	(6,690)
General and administration	(1,465)	145	-	-	26	32	-	-	-	(1,262)
Operating profit	10,077	511	830	165	37	32	-	-	-	11,652
Financing costs	(211)	-	-	-	2	2	-	-	-	(207)
Other financial income (expense)	21	-	-	-	-	-	-	-	-	21
Profit before taxes	9,887	511	830	165	39	34	-	-	-	11,466
Income taxes	(1,671)	(106)	(114)	(31)	(8)	(7)	-	-	(2)	(1,939)
Net income	8,216	405	716	134	31	27	-	-	(2)	9,527
Attributable to										
- Roche shareholders	7,803	400	711	134	31	27	-	-	(2)	9,104
- Non-controlling interests	413	5	5	-	-	-	-	-	-	423
EPS - diluted (CHF)	9.05	0.47	0.81	0.16	0.04	0.03	-	-	-	10.56

14. Roche Group consolidated balance sheet

in millions of CHF	30 June 2021	31 December 2020	31 December 2019*
Non-current assets			
Property, plant and equipment	23,172	22,158	22,173
Right-of-use assets	1,128	1,112	1,145
Goodwill	10,623	9,249	10,295
Intangible assets	12,510	12,017	10,751
Deferred tax assets	5,766	5,459	4,979
Defined benefit plan assets	1,229	967	945
Other non-current assets	2,199	2,234	1,549
Total non-current assets	56,627	53,196	51,837
Current assets			
Inventories	8,319	7,194	6,055
Accounts receivable	11,656	10,154	10,440
Current income tax assets	153	149	237
Other current assets	3,115	3,111	2,664
Marketable securities	3,017	6,607	5,783
Cash and cash equivalents	5,000	5,727	6,075
Total current assets	31,260	32,942	31,254
Total assets	87,887	86,138	83,091
Non-current liabilities			
Long-term debt	(11,285)	(10,220)	(12,668)
Net deferred tax liabilities	(499)	(353)	(298)
Defined benefit plan liabilities	(6,780)	(7,831)	(7,480)
Provisions	(1,467)	(1,453)	(1,515)
Other non-current liabilities	(1,230)	(1,107)	(1,144)
Total non-current liabilities	(21,261)	(20,964)	(23,105)
Current liabilities			
Short-term debt	(3,726)	(3,996)	(1,695)
Current income tax liabilities	(3,473)	(3,679)	(3,838)
Provisions	(1,940)	(1,836)	(2,885)
Accounts payable	(4,241)	(4,121)	(3,822)
Other current liabilities	(11,813)	(11,769)	(11,879)
Total current liabilities	(25,193)	(25,401)	(24,119)
Total liabilities	(46,454)	(46,365)	(47,224)
Total net assets	41,433	39,773	35,867
Equity			
Capital and reserves attributable to Roche shareholders	37,814	36,341	32,747
Equity attributable to non-controlling interests	3,619	3,432	3,120
Total equity	41,433	39,773	35,867

* The balance sheet at 31 December 2019 has been restated following the finalisation of the valuation of the net assets acquired related to the Spark Therapeutics acquisition in 2019.

15. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2021	HY 2020
Cash flows from operating activities		
Cash generated from operations	13,324	13,807
(Increase) decrease in net working capital	(2,616)	(4,817)
Payments made for defined benefit plans	(288)	(284)
Utilisation of provisions	(511)	(505)
Disposal of products	484	130
Other operating cash flows	2	-
Cash flows from operating activities, before income taxes paid	10,395	8,331
Income taxes paid	(2,183)	(1,269)
Total cash flows from operating activities	8,212	7,062
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,759)	(1,614)
Purchase of intangible assets	(335)	(1,524)
Disposal of property, plant and equipment	38	34
Disposal of intangible assets	-	-
Business combinations	(1,822)	(674)
Divestment of subsidiaries	-	-
Interest and dividends received	1	11
Sales of marketable securities	129	206
Purchases of marketable securities	(99)	(111)
Sales (purchases) of money market instruments and time accounts over three months, net	3,633	3,170
Other investing cash flows	258	(294)
Total cash flows from investing activities	44	(796)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	1,391	-
Redemption and repurchase of bonds and notes	(1,266)	-
Increase (decrease) in commercial paper	191	521
Increase (decrease) in other debt	(19)	393
Hedging and collateral arrangements	(324)	196
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(243)	(264)
Principal portion of lease liabilities paid	(187)	(183)
Dividends paid	(7,955)	(7,806)
Equity-settled equity compensation plans, net of transactions in own equity	(644)	(1,380)
Other financing cash flows	-	3
Total cash flows from financing activities	(9,056)	(8,520)
Net effect of currency translation on cash and cash equivalents	73	(51)
Increase (decrease) in cash and cash equivalents	(727)	(2,305)
Cash and cash equivalents at beginning of period	5,727	6,075
Cash and cash equivalents at end of period	5,000	3,770